We dig into: Lilly's decision to stop disclosing its Phase 1 pipeline The Camurus fluid crystal technology deal and what it means for long-acting GLP-1s Eloralintide Lilly's selective amylin agonist and potential dark horse in obesity medicine How eloralintide compares to Novo Nordisk's cagrilintide Why the future of obesity treatment is a toolbox, not a scoreboard The access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gaps Retatrutide , quintuple agonists, and what's coming out of ADA 2026 If you're on Zepbound , Wegovy , Ozempic , or any GLP-1 medication or you're waiting for the next generation of obesity drugs this episode is for you
JCI Insight 6(22):e153732
Pure Med Spa is proud to offer a high-quality, patient-centered program that emphasizes individualized treatment plans, licensed providers, and continuous support
What purity standard should researchers require for retatrutide
The first date of NAFLD/NASH diagnosis was defined as the index date
STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease